Vitebsk Biopharma Factory expects to increase exports by 58% within the Customs Union

July 6, Vitebsk / Diana Kurilo - BELTA /. The creation of a single customs space between Belarus, Russia, and Kazakhstan will allow Vitebsk Biopharma to increase exports by 58% without additional costs. The economic benefits of the triple union have been calculated at the enterprise, the director of the private production unitary enterprise "Vitebsk Biopharma" Arkady Yudasin told a BELTA correspondent. From the moment the Customs Code enters into force - on July 6, an agreement on establishing uniform rules in the field of technical regulation, sanitary, veterinary, and phytosanitary control comes into effect. Thus, certificates for veterinary drugs issued in Belarus will be valid in Russia and Kazakhstan. Previously, to sell its vaccines in these countries, Biopharma was obliged to obtain certificates from their supervisory authorities. According to Arkady Yudasin, the registration of one drug cost the enterprise from $3,000 to $5,000, and it took about 1 year to obtain the documents. According to preliminary calculations, the creation of the customs space will allow Vitebsk Biopharma to increase exports by $233.6 thousand. Increasing export volumes is one of the enterprise's strategic objectives. In the near future, Biopharma plans to significantly increase the volume of supplies to Russia and Kazakhstan of products of its own production in its core business: vaccines, sera, and chemical-pharmaceutical preparations. Currently, a contract has been concluded with a company from Kazakhstan for over 16 thousand euros. The founder of the private production unitary enterprise "Vitebsk Biopharma" is OJSC "Belzoovetsnabproyekt". The authorized capital is Br16.5 billion, of which 98.34% is the state's share, and the rest belongs to business entities of non-state ownership. For January-May of the current year, the volume of production in comparable prices amounted to Br6 billion, which is 26% more compared to the same period last year. The growth rate of new products in January-May was 217.6% and is estimated at Br1.5 billion. The volume of shipped products at current prices for five months reached Br5 billion, which is 28% higher than the same indicators last year. For January-May of the current year, the enterprise increased its net profit by 9 times compared to the same period last year, to Br1.5 billion. Biopharma exports products to Azerbaijan, Turkey, and Kazakhstan. Vitebsk Biopharma is completing the implementation of the innovative project "Expansion of UP "Vitebsk Biopharma", which is carried out according to the state program for the development of veterinary drug production. In accordance with the project, the completion of the construction of the main production building of the enterprise with a total area of 18.7 thousand square meters and the equipping of new production facilities with modern technological equipment that meets GMP requirements are planned. State investments in the project from 2005 to 2010 amounted to Br191.1 billion. At this stage, the enterprise is being inspected by a commission for the commissioning of the second and third start-up complexes, which will produce finished dosage forms, bacterial vaccines, and infusion solutions for veterinary medicine, as well as the production of import-substituting viral vaccines. -0-